Tesla's Market Cap Dips Below Eli Lilly Following Q4 Revenue Miss
Portfolio Pulse from Benzinga Neuro
Tesla Inc. (TSLA) experienced a 12% drop in stock price after a Q4 revenue miss, causing its market cap to fall below that of Eli Lilly (LLY). Eli Lilly's market value increased due to the success of its weight-loss drugs, with shares up 59% for the year. Tesla's earnings report was criticized, and its growth forecasts are weak, while Eli Lilly receives bullish forecasts from analysts, including a potential 140% stock increase by 2028 as predicted by Goldman Sachs.
January 26, 2024 | 12:58 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Tesla's Q4 revenue miss and subsequent stock price drop, along with weak growth forecasts and criticism of its earnings call, suggest a negative short-term impact on its stock.
Tesla's stock price has been directly affected by the Q4 earnings miss and negative analyst sentiment, indicating a likely short-term decline in stock value.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Eli Lilly's market cap has surpassed Tesla's following a surge in its stock price, driven by successful weight-loss drugs and positive analyst forecasts, indicating a positive short-term impact.
Eli Lilly's stock has appreciated due to product success and optimistic analyst projections, suggesting continued short-term upward momentum.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 80